Colossal Biosciences
Alta Charo is the Knowles Professor Emerita of Law & Bioethics at the University of Wisconsin, where for over 30 years she has taught classes on biotechnology policy, food and drug law, public health law and bioethics. Alta served as a David A. Hamburg Inaugural Fellow at the Nuclear Threat Initiative, working in its global biosecurity program. She is also an elected member of the American Academy of Arts and Sciences; the American Association for the Advancement of Science; and the National Academy of Medicine. She was a member of Pres. Clinton’s National Bioethics Advisory Commission, worked as a policy analyst at the congressional Office of Technology Assessment and the US Agency for International Development, and served as a senior policy advisor in the Office of the Commissioner at the FDA, focusing on regulatory approaches to emerging technologies. At the National Academies of Sciences, Engineering and Medicine she co-chaired the committees on guidelines for embryonic stem cell research (2005-2010) and governance of human genome editing (2015-2017), co-founded the forum on regenerative medicine, served on its committee on science technology and law, and now co-chairs its standing committee on “emerging science, technology and innovation.” At present, she is also a member of the World Health Organization’s expert advisory committee on global governance of genome editing, and a member of the organizing committee for the upcoming 2022 US-UK “third international summit on genome editing.”
This person is not in the org chart
This person is not in any offices
Colossal Biosciences
5 followers
At Colossal Biosciences, we endeavor to jumpstart nature’s ancestral heartbeat. To see the woolly mammoth thunder upon the tundra once again. To advance the economics of biology and nutrition. To make humanity more human. And to reawaken the lost wilds of Earth. So we, and our planet can breathe easier. These things, which were not achievable before, are now. In our laboratories. Through our breakthroughs in CRISPR and genetic engineering. We are leading the new charge of bioscience. We accept the responsibility. And we can see the light at the end of it all.